Literature DB >> 10994733

Micronucleus yield and colorimetric test as indicators of damage in patients' lymphocytes after 131I therapy.

C Catena1, D Conti, G Trenta, E Righi, F Breuer, F F Melacrinis, T Montesano, G Ventroni, G Ronga.   

Abstract

UNLABELLED: To estimate the absorbed dose received by patients who underwent 131I therapy, a modified compartmental model of the International Commission on Radiological Protection (ICRP) was used. The activity in plasma and micronucleus (MN) frequency (MN test) were measured before and after therapy. To evaluate whether a correlation exists between lymphocytes and absorbed dose, a colorimetric test, based on the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT test), was used.
METHODS: Twenty patients who underwent 131I therapy were studied. Activity was measured in plasma, and isolated lymphocytes were collected to perform the MN and MTT tests.
RESULTS: The mean MN frequency observed in unexposed patient lymphocytes was comparable with that of healthy subjects. 131I therapy induces a small increase in MN, and a good correlation with the bone marrow absorbed dose was obtained (P = 0.040). A consistent decrease in phytostimulation observed after therapy (MTT test) correlated significantly with bone marrow absorbed dose (P = 0.0085).
CONCLUSION: The MTT test appears to be more reliable than the MN test for evaluating lymphocyte damage induced by 131I therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10994733

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

1.  Cytogenetic and dosimetric effects of (131)I in patients with differentiated thyroid carcinoma: comparison between stimulation with rhTSH and thyroid hormone withdrawal treatments.

Authors:  Márcia Augusta da Silva; Flávia Gomes Silva Valgôde; Júlia Armiliato Gonzalez; Hélio Yoriyaz; Maria Inês Calil Cury Guimarães; Maria Teresa Carvalho Pinto Ribela; Carlos Alberto Buchpiguel; Paolo Bartolini; Kayo Okazaki
Journal:  Radiat Environ Biophys       Date:  2016-03-24       Impact factor: 1.925

2.  Cytogenetic biodosimetry and dose-rate effect after radioiodine therapy for thyroid cancer.

Authors:  Igor K Khvostunov; Vladimir A Saenko; Valeri Krylov; Andrei Rodichev; Shunichi Yamashita
Journal:  Radiat Environ Biophys       Date:  2017-05-19       Impact factor: 1.925

3.  Micronucleus formation in lymphocytes of children from the vicinity of Chernobyl after (131)I therapy.

Authors:  W-U Müller; S Dietl; K Wuttke; C Reiners; J Biko; E Demidchik; C Streffer
Journal:  Radiat Environ Biophys       Date:  2004-04-08       Impact factor: 1.925

4.  Iodine-131 treatment and chromosomal damage: in vivo dose-effect relationship.

Authors:  Taner Erselcan; Selma Sungu; Semra Ozdemir; Bulent Turgut; Derya Dogan; Ozturk Ozdemir
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-28       Impact factor: 9.236

5.  No evidence of chromosome damage in children and adolescents with differentiated thyroid carcinoma after receiving 131I radiometabolic therapy, as evaluated by micronucleus assay and microarray analysis.

Authors:  Giovanni Federico; Giuseppe Boni; Barbara Fabiani; Lisa Fiore; Patrizia Lazzeri; Francesco Massart; Claudio Traino; Carmela Verola; Giuseppe Saggese; Giuliano Mariani; Roberto Scarpato
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-22       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.